{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:42:38Z","timestamp":1789900958938,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>MYD88<\/jats:italic> mutations in chronic lymphocytic leukemia (CLL) are not well characterized. Earlier reports yielded conflicting results in terms of clinicopathologic presentation and prognostic impact of <jats:italic>MYD88<\/jats:italic> mutations in CLL patients. In addition, the morphological and immunophenotypic features of CLL cases carrying <jats:italic>MYD88<\/jats:italic> mutations have not been explored. Finally, the clinical or biologic implications of the canonical L265P <jats:italic>MYD88<\/jats:italic> mutation vs. mutations in other sites of <jats:italic>MYD88<\/jats:italic> within the context of CLL are also unknown. In this study, a cohort of 1779 CLL patients underwent mutational analysis, and 56 (3.1%) cases were found to have <jats:italic>MYD88<\/jats:italic> mutations, including 38 with L265P mutations (designated here as group A) and 18 with non-L265P mutations (group B). Cases with wild type <jats:italic>MYD88<\/jats:italic> were included as controls. There was no morphological difference in cases with and without <jats:italic>MYD88<\/jats:italic> mutations. Immunophenotypically, cases with mutated <jats:italic>MYD88<\/jats:italic> (both groups A and B) more frequently had an atypical immunophenotype when compared to wild type cases. Group A patients were younger and were associated with variable favorable prognostic factors, including less elevated \u03b22-microglobulin level, negative CD38 and ZAP70, higher frequency of mutated <jats:italic>IGHV<\/jats:italic> and isolated del(13q14.3), and lower frequency of del(11q22.3) and mutations of <jats:italic>NOTCH1<\/jats:italic> and <jats:italic>SF3B1<\/jats:italic>. In contrast, group B patients were more similar to CLL patients with wild type <jats:italic>MYD88<\/jats:italic>. There was no difference in time to first treatment when comparing <jats:italic>MYD88<\/jats:italic>-mutated vs. wild type CLL patients before and after stratification according to <jats:italic>IGHV<\/jats:italic> mutation status. In summary, <jats:italic>MYD88<\/jats:italic> mutations are uncommon in CLL and cases with L265P mutation have distinctive clinical, immunophenotypic, cytogenetic, and molecular features. There is no significant impact of <jats:italic>MYD88<\/jats:italic> mutations on time to first treatment in CLL.<\/jats:p>","DOI":"10.1038\/s41408-020-00351-w","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T04:12:03Z","timestamp":1598415123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features"],"prefix":"10.1038","volume":"10","author":[{"given":"Wen","family":"Shuai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-1459","authenticated-orcid":false,"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Routbort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7110-3814","authenticated-orcid":false,"given":"Shimin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7758-6116","authenticated-orcid":false,"given":"Peng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-3584","authenticated-orcid":false,"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. James","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenya","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-5959","authenticated-orcid":false,"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beenu","family":"Thakral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6821-4556","authenticated-orcid":false,"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"351_CR1","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek, M. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111, 5446\u20135456 (2008).","journal-title":"Blood"},{"key":"351_CR2","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3109\/10428194.2013.827785","volume":"55","author":"V Mak","year":"2014","unstructured":"Mak, V. et al. Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008. Leukemia Lymphoma 55, 824\u2013827 (2014).","journal-title":"Leukemia Lymphoma"},{"key":"351_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nrclinonc.2010.101","volume":"7","author":"CS Tam","year":"2010","unstructured":"Tam, C. S. & Keating, M. J. Chemoimmunotherapy of chronic lymphocytic leukemia. Nat. Rev. Clin. Oncol. 7, 521\u2013532 (2010).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"351_CR4","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","volume":"101","author":"A Wiestner","year":"2003","unstructured":"Wiestner, A. et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101, 4944\u20134951 (2003).","journal-title":"Blood"},{"key":"351_CR5","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1038\/sj.leu.2403147","volume":"17","author":"J Durig","year":"2003","unstructured":"Durig, J. et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 17, 2426\u20132434 (2003).","journal-title":"Leukemia"},{"key":"351_CR6","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","volume":"100","author":"A Krober","year":"2002","unstructured":"Krober, A. et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100, 1410\u20131416 (2002).","journal-title":"Blood"},{"key":"351_CR7","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood-2015-10-620864","volume":"127","author":"SA Parikh","year":"2016","unstructured":"Parikh, S. A., Strati, P., Tsang, M., West, C. P. & Shanafelt, T. D. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood 127, 1752\u20131760 (2016).","journal-title":"Blood"},{"key":"351_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrclinonc.2010.167","volume":"8","author":"P Cramer","year":"2011","unstructured":"Cramer, P. & Hallek, M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat. Rev. Clin. Oncol. 8, 38\u201347 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"351_CR9","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G. & Stevenson, F. K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848\u20131854 (1999).","journal-title":"Blood"},{"key":"351_CR10","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"RN Damle","year":"1999","unstructured":"Damle, R. N. et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94, 1840\u20131847 (1999).","journal-title":"Blood"},{"key":"351_CR11","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1056\/NEJMoa023143","volume":"348","author":"M Crespo","year":"2003","unstructured":"Crespo, M. et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348, 1764\u20131775 (2003).","journal-title":"N. Engl. J. Med."},{"key":"351_CR12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1182\/blood-2005-04-1677","volume":"107","author":"JL Binet","year":"2006","unstructured":"Binet, J. L. et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 107, 859\u2013861 (2006).","journal-title":"Blood"},{"key":"351_CR13","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/modpathol.2017.58","volume":"30","author":"A Onaindia","year":"2017","unstructured":"Onaindia, A., Medeiros, L. J. & Patel, K. P. Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Mod. Pathol. 30, 1338\u20131366 (2017).","journal-title":"Mod. Pathol."},{"key":"351_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau, D. A. et al. Mutations driving CLL and their evolution in progression and relapse. Nature 526, 525\u2013530 (2015).","journal-title":"Nature"},{"key":"351_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature14666","volume":"526","author":"XS Puente","year":"2015","unstructured":"Puente, X. S. et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 526, 519\u2013524 (2015).","journal-title":"Nature"},{"key":"351_CR16","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nature09121","volume":"465","author":"SC Lin","year":"2010","unstructured":"Lin, S. C., Lo, Y. C. & Wu, H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR\/IL-1R signalling. Nature 465, 885\u2013890 (2010).","journal-title":"Nature"},{"key":"351_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115\u2013119 (2011).","journal-title":"Nature"},{"key":"351_CR18","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon, S. P. et al. MYD88 L265P somatic mutation in Waldenstrom\u2019s macroglobulinemia. N. Engl. J. Med. 367, 826\u2013833 (2012).","journal-title":"N. Engl. J. Med."},{"key":"351_CR19","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","volume":"123","author":"SP Treon","year":"2014","unstructured":"Treon, S. P. et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 123, 2791\u20132796 (2014).","journal-title":"Blood"},{"key":"351_CR20","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","volume":"123","author":"ZR Hunter","year":"2014","unstructured":"Hunter, Z. R. et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 123, 1637\u20131646 (2014).","journal-title":"Blood"},{"key":"351_CR21","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1158\/1078-0432.CCR-15-1525","volume":"22","author":"J Rovira","year":"2016","unstructured":"Rovira, J. et al. MYD88 L265P mutations, but no other variants, identify a subpopulation of DLBCL patients of activated B-cell origin, extranodal involvement, and poor outcome. Clin. Cancer Res. 22, 2755\u20132764 (2016).","journal-title":"Clin. Cancer Res."},{"key":"351_CR22","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-16-1922","volume":"23","author":"S Dubois","year":"2017","unstructured":"Dubois, S. et al. Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large B-cell lymphoma: analysis of 361 cases. Clin. Cancer Res. 23, 2232\u20132244 (2017).","journal-title":"Clin. Cancer Res."},{"key":"351_CR23","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1182\/blood-2013-12-543306","volume":"123","author":"A Martinez-Trillos","year":"2014","unstructured":"Martinez-Trillos, A. et al. Mutations in TLR\/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood 123, 3790\u20133796 (2014).","journal-title":"Blood"},{"key":"351_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/leu.2013.263","volume":"28","author":"S Jeromin","year":"2014","unstructured":"Jeromin, S. et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 28, 108\u2013117 (2014).","journal-title":"Leukemia"},{"key":"351_CR25","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","volume":"365","author":"L Wang","year":"2011","unstructured":"Wang, L. et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365, 2497\u20132506 (2011).","journal-title":"N. Engl. J. Med."},{"key":"351_CR26","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.18632\/oncotarget.3101","volume":"6","author":"Y Xia","year":"2015","unstructured":"Xia, Y. et al. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans. Oncotarget 6, 5426\u20135434 (2015).","journal-title":"Oncotarget"},{"key":"351_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0014-y","volume":"7","author":"SC Qin","year":"2017","unstructured":"Qin, S. C. et al. MYD88 mutations predict unfavorable prognosis in chronic lymphocytic leukemia patients with mutated IGHV gene. Blood Cancer J. 7, 651 (2017).","journal-title":"Blood Cancer J."},{"key":"351_CR28","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1182\/blood-2015-05-648634","volume":"126","author":"P Baliakas","year":"2015","unstructured":"Baliakas, P. et al. Prognostic relevance of MYD88 mutations in CLL: the jury is still out. Blood 126, 1043\u20131044 (2015).","journal-title":"Blood"},{"key":"351_CR29","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","volume":"152","author":"DA Landau","year":"2013","unstructured":"Landau, D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714\u2013726 (2013).","journal-title":"Cell"},{"key":"351_CR30","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/leu.2016.330","volume":"31","author":"C Baer","year":"2017","unstructured":"Baer, C., Dicker, F., Kern, W., Haferlach, T. & Haferlach, C. Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia. Leukemia 31, 1355\u20131362 (2017).","journal-title":"Leukemia"},{"key":"351_CR31","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","volume":"121","author":"D Rossi","year":"2013","unstructured":"Rossi, D. et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 121, 1403\u20131412 (2013).","journal-title":"Blood"},{"key":"351_CR32","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1182\/blood-2015-10-678490","volume":"127","author":"A Martinez-Trillos","year":"2016","unstructured":"Martinez-Trillos, A. et al. Clinical impact of MYD88 mutations in chronic lymphocytic leukemia. Blood 127, 1611\u20131613 (2016).","journal-title":"Blood"},{"key":"351_CR33","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/modpathol.3800145","volume":"17","author":"JH Admirand","year":"2004","unstructured":"Admirand, J. H. et al. Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Mod. Pathol. 17, 954\u2013961 (2004).","journal-title":"Mod. Pathol."},{"key":"351_CR34","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1158\/1078-0432.CCR-17-1597","volume":"24","author":"JD Khoury","year":"2018","unstructured":"Khoury, J. D. et al. Validation of immunohistochemical assays for integral biomarkers in the NCI-MATCH EAY131 clinical trial. Clin. Cancer Res. 24, 521\u2013531 (2018).","journal-title":"Clin. Cancer Res."},{"key":"351_CR35","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s11899-019-00533-9","volume":"14","author":"N Sukswai","year":"2019","unstructured":"Sukswai, N. & Khoury, J. D. Immunohistochemistry innovations for diagnosis and tissue-based biomarker detection. Curr. Hematol. Malign. Rep. 14, 368\u2013375 (2019).","journal-title":"Curr. Hematol. Malign. Rep."},{"key":"351_CR36","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/bjh.15877","volume":"185","author":"B Hu","year":"2019","unstructured":"Hu, B. et al. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br. J. Haematol. 185, 852\u2013864 (2019).","journal-title":"Br. J. Haematol."},{"key":"351_CR37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature10113","volume":"475","author":"XS Puente","year":"2011","unstructured":"Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101\u2013105 (2011).","journal-title":"Nature"},{"key":"351_CR38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.humpath.2018.07.030","volume":"82","author":"S Garces","year":"2018","unstructured":"Garces, S. et al. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. Hum. Pathol. 82, 215\u2013231 (2018).","journal-title":"Hum. Pathol."},{"key":"351_CR39","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1309\/3G1XDX0DVHBNVKB4","volume":"124","author":"S Konoplev","year":"2005","unstructured":"Konoplev, S., Medeiros, L. J., Bueso-Ramos, C. E., Jorgensen, J. L. & Lin, P. Immunophenotypic profile of lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinemia. Am. J. Clin. Pathol. 124, 414\u2013420 (2005).","journal-title":"Am. J. Clin. Pathol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00351-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00351-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00351-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:33:27Z","timestamp":1670250807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00351-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-00351-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,26]]},"assertion":[{"value":"31 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"86"}}